2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Objective To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. Methods We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment,...
Saved in:
| Published in | Arthritis care & research (2010) Vol. 73; no. 7; pp. 924 - 939 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.07.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2151-464X 2151-4658 2151-4658 |
| DOI | 10.1002/acr.24596 |
Cover
| Abstract | Objective
To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.
Methods
We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
Results
The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).
Conclusion
This clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities. |
|---|---|
| AbstractList | Objective
To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.
Methods
We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
Results
The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).
Conclusion
This clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities. Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide general guidance for commonly encountered clinical scenarios. The recommendations do not dictate the care for an individual patient. The ACR considers adherence to the recommendations described in this guideline to be voluntary, with the ultimate determination regarding their application to be made by the clinicians in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions, or drug formularies or other third-party analyses. Third parties that cite ACR guidelines should state that these recommendations are not meant for this purpose. These recommendations cannot adequately convey all uncertainties and nuances of patient care. The American College of Rheumatology is an independent, professional, medical and scientific society that does not guarantee, warrant, or endorse any commercial product or service. To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.OBJECTIVETo develop updated guidelines for the pharmacologic management of rheumatoid arthritis.We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.METHODSWe developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.The guideline addresses treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).RESULTSThe guideline addresses treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).This clinical practice guideline is intended to serve as a tool to support clinician and patient decision-making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision-making process based on patients' values, goals, preferences, and comorbidities.CONCLUSIONThis clinical practice guideline is intended to serve as a tool to support clinician and patient decision-making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision-making process based on patients' values, goals, preferences, and comorbidities. ObjectiveTo develop updated guidelines for the pharmacologic management of rheumatoid arthritis.MethodsWe developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.ResultsThe guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).ConclusionThis clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities. To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. The guideline addresses treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional). This clinical practice guideline is intended to serve as a tool to support clinician and patient decision-making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision-making process based on patients' values, goals, preferences, and comorbidities. |
| Author | Barbour, Kamil E. Kerr, Gail Kremer, Joel Karam, Basil S. Russell, Linda A. George, Michael Nakamura, Mary C. England, Bryant R. Barton, Jennifer L. Huston, Kent Kwas Navarro-Millán, Iris Turner, Amy S. Deane, Kevin D. Yaacoub, Sally Chamseddine, Fatimah Cappelli, Laura Smith, Benjamin J. Johnson, Sindhu R. Schwab, Pascale Mirza, Reza Genovese, Mark Kahale, Lara Turgunbaev, Marat Fraenkel, Liana Bathon, Joan M. Sparks, Jeffrey A. Khamis, Assem M. Akl, Elie A. Arayssi, Thurayya St.Clair, E. William Venkatachalam, Shilpa Singh, Namrata Singh, Jasvinder A. Weinblatt, Michael E. Carandang, Kristine Al‐Gibbawi, Mounir Baker, Joshua F. |
| AuthorAffiliation | 7 University of Colorado, Aurora 11 Albany Medical College and The Center for Rheumatology, Albany, New York 18 American University of Beirut, Beirut, Lebanon 26 University of Toronto, Toronto, Ontario, Canada 17 Global Healthy Living Foundation, Upper Nyack, New York 28 American College of Rheumatology, Atlanta, Georgia 20 Centers for Disease Control and Prevention, Atlanta, Georgia 16 Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 23 University of Pennsylvania, Philadelphia 14 University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama 2 Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, New York 9 The Center for Rheumatic Disease/Allergy and Immunology, Kansas City, Missouri 12 University of California, San Francisco 13 Hospital for Special Surgery, New York, New York 5 Weill Cornell Medicine–Qatar, Doha, Qatar 25 Weill Cornell Medicine, New York, New York 15 State University College of Med |
| AuthorAffiliation_xml | – name: 1 Berkshire Medical Center, Pittsfield, Massachusetts, and Yale University School of Medicine, New Haven, Connecticut – name: 5 Weill Cornell Medicine–Qatar, Doha, Qatar – name: 28 American College of Rheumatology, Atlanta, Georgia – name: 24 Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada – name: 6 University of California, San Diego – name: 19 Corporal Michael J. Crescenz VA Medical Center and the University of Pennsylvania, Philadelphia, Pennsylvania – name: 22 Johns Hopkins Medicine, Baltimore, Maryland – name: 4 Duke University Medical Center, Durham, North Carolina – name: 16 Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts – name: 21 Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon – name: 3 University of Nebraska Medical Center and VA Nebraska–Western Iowa Health Care System, Omaha, Nebraska – name: 2 Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, New York – name: 17 Global Healthy Living Foundation, Upper Nyack, New York – name: 23 University of Pennsylvania, Philadelphia – name: 15 State University College of Medicine School of Physician Assistant Practice, Tallahassee – name: 12 University of California, San Francisco – name: 14 University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama – name: 18 American University of Beirut, Beirut, Lebanon – name: 20 Centers for Disease Control and Prevention, Atlanta, Georgia – name: 9 The Center for Rheumatic Disease/Allergy and Immunology, Kansas City, Missouri – name: 26 University of Toronto, Toronto, Ontario, Canada – name: 10 Veterans Affairs Medical Center, Georgetown and Howard University, Washington, DC – name: 13 Hospital for Special Surgery, New York, New York – name: 8 Stanford University Medical Center, Palo Alto, California – name: 25 Weill Cornell Medicine, New York, New York – name: 11 Albany Medical College and The Center for Rheumatology, Albany, New York – name: 27 University of Washington, Seattle – name: 7 University of Colorado, Aurora |
| Author_xml | – sequence: 1 givenname: Liana orcidid: 0000-0002-6148-610X surname: Fraenkel fullname: Fraenkel, Liana email: liana.fraenkel@yale.edu organization: Berkshire Medical Center, Pittsfield, Massachusetts, and Yale University School of Medicine – sequence: 2 givenname: Joan M. surname: Bathon fullname: Bathon, Joan M. organization: New York Presbyterian Hospital – sequence: 3 givenname: Bryant R. orcidid: 0000-0002-9649-3588 surname: England fullname: England, Bryant R. organization: University of Nebraska Medical Center and VA Nebraska‐Western Iowa Health Care System – sequence: 4 givenname: E. William surname: St.Clair fullname: St.Clair, E. William organization: Duke University Medical Center – sequence: 5 givenname: Thurayya surname: Arayssi fullname: Arayssi, Thurayya organization: Weill Cornell Medicine–Qatar – sequence: 6 givenname: Kristine orcidid: 0000-0002-0159-6374 surname: Carandang fullname: Carandang, Kristine organization: University of California – sequence: 7 givenname: Kevin D. orcidid: 0000-0003-2211-4861 surname: Deane fullname: Deane, Kevin D. organization: University of Colorado – sequence: 8 givenname: Mark orcidid: 0000-0001-5294-4503 surname: Genovese fullname: Genovese, Mark organization: Stanford University Medical Center – sequence: 9 givenname: Kent Kwas surname: Huston fullname: Huston, Kent Kwas organization: The Center for Rheumatic Disease/Allergy and Immunology – sequence: 10 givenname: Gail surname: Kerr fullname: Kerr, Gail organization: Georgetown and Howard University – sequence: 11 givenname: Joel orcidid: 0000-0001-6674-9901 surname: Kremer fullname: Kremer, Joel organization: Albany Medical College and The Center for Rheumatology – sequence: 12 givenname: Mary C. surname: Nakamura fullname: Nakamura, Mary C. organization: University of California – sequence: 13 givenname: Linda A. surname: Russell fullname: Russell, Linda A. organization: Hospital for Special Surgery – sequence: 14 givenname: Jasvinder A. orcidid: 0000-0003-3485-0006 surname: Singh fullname: Singh, Jasvinder A. organization: University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center – sequence: 15 givenname: Benjamin J. orcidid: 0000-0002-6612-0473 surname: Smith fullname: Smith, Benjamin J. organization: Florida State University College of Medicine School of Physician Assistant Practice – sequence: 16 givenname: Jeffrey A. orcidid: 0000-0002-5556-4618 surname: Sparks fullname: Sparks, Jeffrey A. organization: Brigham and Women’s Hospital and Harvard Medical School – sequence: 17 givenname: Shilpa surname: Venkatachalam fullname: Venkatachalam, Shilpa organization: Global Healthy Living Foundation – sequence: 18 givenname: Michael E. surname: Weinblatt fullname: Weinblatt, Michael E. organization: Brigham and Women’s Hospital and Harvard Medical School – sequence: 19 givenname: Mounir surname: Al‐Gibbawi fullname: Al‐Gibbawi, Mounir organization: American University of Beirut – sequence: 20 givenname: Joshua F. orcidid: 0000-0003-0799-7563 surname: Baker fullname: Baker, Joshua F. organization: Corporal Michael J. Crescenz VA Medical Center and the University of Pennsylvania – sequence: 21 givenname: Kamil E. orcidid: 0000-0003-0546-6742 surname: Barbour fullname: Barbour, Kamil E. organization: Centers for Disease Control and Prevention – sequence: 22 givenname: Jennifer L. surname: Barton fullname: Barton, Jennifer L. organization: Oregon Health & Science University and VA Portland Health Care System – sequence: 23 givenname: Laura orcidid: 0000-0003-2795-7059 surname: Cappelli fullname: Cappelli, Laura organization: Johns Hopkins Medicine – sequence: 24 givenname: Fatimah surname: Chamseddine fullname: Chamseddine, Fatimah organization: American University of Beirut – sequence: 25 givenname: Michael orcidid: 0000-0002-0398-2308 surname: George fullname: George, Michael organization: University of Pennsylvania – sequence: 26 givenname: Sindhu R. orcidid: 0000-0003-0591-2976 surname: Johnson fullname: Johnson, Sindhu R. organization: University of Toronto – sequence: 27 givenname: Lara surname: Kahale fullname: Kahale, Lara organization: American University of Beirut – sequence: 28 givenname: Basil S. surname: Karam fullname: Karam, Basil S. organization: American University of Beirut – sequence: 29 givenname: Assem M. orcidid: 0000-0002-5567-7065 surname: Khamis fullname: Khamis, Assem M. organization: American University of Beirut – sequence: 30 givenname: Iris orcidid: 0000-0002-9540-6614 surname: Navarro-Millán fullname: Navarro-Millán, Iris organization: Weill Cornell Medicine – sequence: 31 givenname: Reza surname: Mirza fullname: Mirza, Reza organization: University of Toronto – sequence: 32 givenname: Pascale surname: Schwab fullname: Schwab, Pascale organization: Oregon Health & Science University and VA Portland Health Care System – sequence: 33 givenname: Namrata surname: Singh fullname: Singh, Namrata organization: University of Washington – sequence: 34 givenname: Marat surname: Turgunbaev fullname: Turgunbaev, Marat organization: American College of Rheumatology – sequence: 35 givenname: Amy S. orcidid: 0000-0001-7695-2022 surname: Turner fullname: Turner, Amy S. organization: American College of Rheumatology – sequence: 36 givenname: Sally orcidid: 0000-0003-0819-1561 surname: Yaacoub fullname: Yaacoub, Sally organization: American University of Beirut – sequence: 37 givenname: Elie A. surname: Akl fullname: Akl, Elie A. organization: American University of Beirut |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34101387$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kV1LHDEYhUNRqrVe9A-UQG_qxWo-ZyY3hWWptiAUxIJehUzmnd1IZmKTjGX_fbPdVVTa3CQvec7hJOcd2hvDCAh9oOSUEsLOjI2nTEhVvUGHjEo6E5Vs9p7O4uYAHad0R8rirGm4eosOuKCE8qY-RLeMMIrnA0RnzYgXwXtYAg49vlrBNJgcfFiu8cXkOvBuBNyHiPMK8HUEkwcY83PWdXge8yq67NJ7tN8bn-B4tx-hn-dfrxffZpc_Lr4v5pczK4mqZhJYBRwaW1luBe9UC2Vk0nZGSehA9a0RXLRtXVemryrDwSjatqozxjZW8iP0Zet7P7UDdLZEisbr--gGE9c6GKdf3oxupZfhQStWcyJoMfi8M4jh1wQp68ElC96bEcKUNJNcMUpVwwv66RV6F6Y4lucVSkjZ1FxsEn18nugpyuOvF-BsC9gYUorQa-uyyS5sAjqvKdGbanWpVv-ttihOXikeTf_F7tx_Ow_r_4N6vrjaKv4AHIqzrA |
| CitedBy_id | crossref_primary_10_1038_s41467_025_57361_0 crossref_primary_10_1136_rmdopen_2024_005062 crossref_primary_10_1136_rmdopen_2023_003839 crossref_primary_10_5435_JAAOSGlobal_D_22_00209 crossref_primary_10_1007_s12325_024_02818_9 crossref_primary_10_1007_s40744_021_00399_5 crossref_primary_10_1136_ard_2023_224190 crossref_primary_10_1016_j_reuma_2024_09_007 crossref_primary_10_14412_1996_7012_2024_5_65_74 crossref_primary_10_1016_j_semarthrit_2023_152341 crossref_primary_10_1038_s41584_024_01120_w crossref_primary_10_3899_jrheum_2022_1008 crossref_primary_10_1016_j_jpba_2022_115109 crossref_primary_10_26693_jmbs08_01_208 crossref_primary_10_1097_RHU_0000000000001952 crossref_primary_10_1097_MD_0000000000036982 crossref_primary_10_1097_RHU_0000000000001956 crossref_primary_10_35366_114746 crossref_primary_10_2196_48989 crossref_primary_10_3389_fphar_2024_1383663 crossref_primary_10_1136_ard_2023_224185 crossref_primary_10_1007_s43441_022_00492_z crossref_primary_10_3390_rheumato1010005 crossref_primary_10_34921_amj_2022_4_023 crossref_primary_10_1002_acr2_11503 crossref_primary_10_1093_rheumatology_keac709 crossref_primary_10_3390_biomedicines12061364 crossref_primary_10_3389_fimmu_2022_942642 crossref_primary_10_1007_s00296_025_05804_8 crossref_primary_10_1111_1756_185X_15199 crossref_primary_10_1136_bmjopen_2021_056545 crossref_primary_10_1177_1759720X221076211 crossref_primary_10_1016_j_nic_2023_07_008 crossref_primary_10_3390_ijms23031246 crossref_primary_10_1016_j_semarthrit_2022_152076 crossref_primary_10_1007_s10067_024_07084_2 crossref_primary_10_1002_mnfr_202200429 crossref_primary_10_1097_RHU_0000000000001972 crossref_primary_10_1136_rmdopen_2023_003858 crossref_primary_10_1186_s13018_023_03764_y crossref_primary_10_1136_rmdopen_2023_003851 crossref_primary_10_1186_s42358_024_00396_6 crossref_primary_10_1002_acr2_11621 crossref_primary_10_1016_j_semarthrit_2022_152041 crossref_primary_10_1038_s41598_023_50379_8 crossref_primary_10_1136_bmjnph_2023_000674 crossref_primary_10_3389_jpps_2023_11135 crossref_primary_10_14412_1996_7012_2024_6_98_106 crossref_primary_10_1097_MD_0000000000035513 crossref_primary_10_1002_acr2_11728 crossref_primary_10_1016_j_semarthrit_2023_152349 crossref_primary_10_3390_jcm12134527 crossref_primary_10_7759_cureus_44982 crossref_primary_10_1080_14656566_2023_2297798 crossref_primary_10_1016_j_mtcomm_2023_105877 crossref_primary_10_1016_j_semarthrit_2024_152535 crossref_primary_10_1093_mr_road102 crossref_primary_10_1186_s12911_024_02696_9 crossref_primary_10_1093_mr_roac017 crossref_primary_10_1016_j_lanwpc_2023_100925 crossref_primary_10_1007_s40744_024_00725_7 crossref_primary_10_1016_j_reuma_2024_02_002 crossref_primary_10_35366_108061 crossref_primary_10_1186_s13075_024_03362_1 crossref_primary_10_1136_rmdopen_2023_003918 crossref_primary_10_1016_j_clinthera_2023_06_024 crossref_primary_10_1002_14651858_CD014897 crossref_primary_10_1007_s10238_024_01478_x crossref_primary_10_1007_s11926_023_01117_6 crossref_primary_10_1177_17534666221135314 crossref_primary_10_1007_s00393_022_01237_x crossref_primary_10_1016_j_eimc_2023_07_005 crossref_primary_10_1002_acr2_11443 crossref_primary_10_1109_TCBB_2022_3191392 crossref_primary_10_1002_acr2_11442 crossref_primary_10_1007_s40744_023_00609_2 crossref_primary_10_1136_bcr_2021_246863 crossref_primary_10_3389_fimmu_2024_1484143 crossref_primary_10_1186_s41927_024_00412_8 crossref_primary_10_1016_j_cct_2023_107327 crossref_primary_10_1016_j_intimp_2024_113769 crossref_primary_10_47360_1995_4484_2023_435_449 crossref_primary_10_1136_annrheumdis_2021_221841 crossref_primary_10_4103_bbrj_bbrj_16_24 crossref_primary_10_1136_rmdopen_2022_002898 crossref_primary_10_1016_j_berh_2022_101773 crossref_primary_10_47360_1995_4484_2024_262_279 crossref_primary_10_1002_acr2_11548 crossref_primary_10_1007_s40266_024_01125_w crossref_primary_10_1007_s40264_024_01478_6 crossref_primary_10_1186_s43166_022_00162_w crossref_primary_10_1007_s00296_024_05544_1 crossref_primary_10_1093_mr_roac032 crossref_primary_10_1136_ard_2022_222784 crossref_primary_10_1007_s10067_023_06825_z crossref_primary_10_19127_mbsjohs_1188195 crossref_primary_10_1155_2024_7693602 crossref_primary_10_1002_hep_32689 crossref_primary_10_2147_IJN_S365523 crossref_primary_10_1007_s10067_023_06847_7 crossref_primary_10_3390_biomedicines11092418 crossref_primary_10_1016_j_jaci_2023_06_004 crossref_primary_10_1016_j_medcle_2024_05_008 crossref_primary_10_1016_S2213_2600_22_00186_2 crossref_primary_10_1016_j_medcli_2024_05_007 crossref_primary_10_1080_03007995_2024_2416979 crossref_primary_10_1186_s13018_024_05429_w crossref_primary_10_2147_BTT_S361164 crossref_primary_10_3390_ijms241311012 crossref_primary_10_1186_s42358_024_00352_4 crossref_primary_10_1002_acr2_11656 crossref_primary_10_1007_s40265_024_02059_8 crossref_primary_10_1016_j_berh_2025_102036 crossref_primary_10_1371_journal_pone_0280234 crossref_primary_10_3390_jcm12020527 crossref_primary_10_3390_jcm13010048 crossref_primary_10_1016_j_semarthrit_2024_152563 crossref_primary_10_3390_jcm14062107 crossref_primary_10_18553_jmcp_2023_23277 crossref_primary_10_1016_j_rcsop_2023_100296 crossref_primary_10_18553_jmcp_2023_29_10_1109 crossref_primary_10_1016_S2665_9913_24_00021_3 crossref_primary_10_1080_14737159_2022_2020648 crossref_primary_10_1007_s41030_024_00262_2 crossref_primary_10_1007_s11926_024_01149_6 crossref_primary_10_1002_acr2_11406 crossref_primary_10_1136_rmdopen_2021_002012 crossref_primary_10_4078_jrd_2023_0045 crossref_primary_10_7717_peerj_18631 crossref_primary_10_1007_s10067_023_06519_6 crossref_primary_10_1016_j_ejim_2023_08_025 crossref_primary_10_1002_acr2_11652 crossref_primary_10_1007_s40744_023_00552_2 crossref_primary_10_1002_acr2_11530 crossref_primary_10_1016_j_reumae_2024_02_003 crossref_primary_10_1016_j_eimce_2023_07_009 crossref_primary_10_1155_2024_8040681 crossref_primary_10_4103_injr_injr_30_23 crossref_primary_10_1007_s40744_022_00483_4 crossref_primary_10_1007_s10067_024_07186_x crossref_primary_10_1007_s40744_024_00674_1 crossref_primary_10_4103_injr_injr_157_21 crossref_primary_10_1111_joim_13505 crossref_primary_10_1155_2022_5268706 crossref_primary_10_1136_rapm_2024_105651 crossref_primary_10_1136_ard_2023_224476 crossref_primary_10_26442_20795696_2023_4_202366 crossref_primary_10_4078_jrd_2024_0026 crossref_primary_10_1016_j_jbspin_2024_105798 crossref_primary_10_1111_joim_13743 crossref_primary_10_1016_j_berh_2024_102019 crossref_primary_10_1007_s40744_024_00651_8 crossref_primary_10_1080_14712598_2022_2066972 crossref_primary_10_26416_Farm_217_2_2024_9493 crossref_primary_10_3390_ijerph19106102 crossref_primary_10_3892_etm_2024_12499 crossref_primary_10_1016_j_semarthrit_2024_152465 crossref_primary_10_3390_ph17070963 crossref_primary_10_1016_j_jsps_2023_101777 crossref_primary_10_1093_rheumatology_kead088 crossref_primary_10_3390_medicina60081339 crossref_primary_10_47102_annals_acadmedsg_2023262 crossref_primary_10_2147_DHPS_S492887 crossref_primary_10_1007_s10067_023_06814_2 crossref_primary_10_1016_S2665_9913_24_00230_3 crossref_primary_10_1007_s11897_022_00581_y crossref_primary_10_3390_diagnostics12071702 crossref_primary_10_1136_rmdopen_2024_004389 crossref_primary_10_1016_j_rdc_2023_07_002 crossref_primary_10_1016_j_biopha_2022_113614 crossref_primary_10_1016_j_csbj_2023_02_050 crossref_primary_10_1093_rheumatology_keae041 crossref_primary_10_1093_rheumatology_kead075 crossref_primary_10_3390_medicina59111960 crossref_primary_10_1016_j_ijbiomac_2023_124047 crossref_primary_10_1016_j_cmi_2024_09_014 crossref_primary_10_1016_j_reuma_2023_05_002 crossref_primary_10_1177_1759720X231158618 crossref_primary_10_1164_rccm_202406_1254CI crossref_primary_10_1371_journal_pone_0305467 crossref_primary_10_3390_vaccines11101610 crossref_primary_10_1186_s41927_023_00368_1 crossref_primary_10_1080_14712598_2024_2384000 crossref_primary_10_1111_1756_185X_14616 crossref_primary_10_7759_cureus_72486 crossref_primary_10_1016_j_semarthrit_2024_152364 crossref_primary_10_3899_jrheum_211017 crossref_primary_10_3892_etm_2023_12067 crossref_primary_10_1016_j_reuma_2022_12_003 crossref_primary_10_1136_ard_2024_225746 crossref_primary_10_2147_DDDT_S388932 crossref_primary_10_1080_09638288_2024_2353855 crossref_primary_10_3390_biology13100818 crossref_primary_10_1016_j_jorep_2023_100196 crossref_primary_10_1093_rheumatology_keae275 crossref_primary_10_1007_s40477_023_00843_y crossref_primary_10_3389_fphar_2024_1376262 crossref_primary_10_4254_wjh_v15_i5_699 crossref_primary_10_1016_j_coph_2022_102308 crossref_primary_10_1002_cpt_2866 crossref_primary_10_1016_j_coph_2022_102304 crossref_primary_10_3390_app122211535 crossref_primary_10_1007_s10787_022_00936_w crossref_primary_10_1016_j_jhep_2022_07_003 crossref_primary_10_1080_14737167_2025_2451141 crossref_primary_10_1111_fcp_13050 crossref_primary_10_1016_S2665_9913_23_00211_4 crossref_primary_10_1016_j_biopha_2022_113518 crossref_primary_10_1016_j_semarthrit_2023_152190 crossref_primary_10_1007_s40744_022_00500_6 crossref_primary_10_7759_cureus_60558 crossref_primary_10_2147_PPA_S374445 crossref_primary_10_1038_s41598_023_37010_6 crossref_primary_10_1016_j_jbspin_2023_105633 crossref_primary_10_3390_ph18010022 crossref_primary_10_5114_reum_199740 crossref_primary_10_1016_j_reumae_2024_11_008 crossref_primary_10_3899_jrheum_2023_1062 crossref_primary_10_3390_jcm13082355 crossref_primary_10_1002_bmm2_12104 crossref_primary_10_23736_S1973_9087_22_07833_9 crossref_primary_10_1136_rmdopen_2023_003075 crossref_primary_10_1136_rmdopen_2023_003196 crossref_primary_10_1007_s40264_024_01490_w crossref_primary_10_1371_journal_pone_0279632 crossref_primary_10_2174_0115733971288433240408062359 crossref_primary_10_1111_imr_13358 crossref_primary_10_1177_23971983231222368 crossref_primary_10_4078_jrd_2024_0077 crossref_primary_10_1080_17512433_2022_2120468 crossref_primary_10_1002_art_42928 crossref_primary_10_3390_cells11030452 crossref_primary_10_1007_s10067_023_06588_7 crossref_primary_10_1007_s12274_023_5877_6 crossref_primary_10_1093_rheumatology_kead390 crossref_primary_10_1093_rheumatology_keae486 crossref_primary_10_1080_08916934_2024_2330392 crossref_primary_10_1016_j_autrev_2022_103031 crossref_primary_10_1002_acr_25442 crossref_primary_10_1186_s13075_023_03072_0 crossref_primary_10_3390_ijms231810719 crossref_primary_10_1177_09733698241229913 crossref_primary_10_1016_j_jbspin_2024_105732 crossref_primary_10_1016_j_jtcme_2024_08_005 crossref_primary_10_1186_s13063_024_08372_7 crossref_primary_10_1038_s41598_022_21160_0 crossref_primary_10_1007_s40744_023_00544_2 crossref_primary_10_1111_1756_185X_14778 crossref_primary_10_1136_rmdopen_2024_004476 crossref_primary_10_7759_cureus_71111 crossref_primary_10_1016_j_berh_2021_101741 crossref_primary_10_1111_1756_185X_14419 crossref_primary_10_1097_RHU_0000000000001818 crossref_primary_10_1016_j_jbspin_2022_105491 crossref_primary_10_1016_j_reumae_2021_08_004 crossref_primary_10_1111_ddg_15675 crossref_primary_10_1016_j_berh_2021_101739 crossref_primary_10_1080_1744666X_2023_2299729 crossref_primary_10_17925_RMD_2023_2_1_17 crossref_primary_10_1097_FJC_0000000000001470 crossref_primary_10_1186_s13256_024_04730_w crossref_primary_10_1016_j_coph_2022_102226 crossref_primary_10_1016_j_coph_2022_102227 crossref_primary_10_1016_j_cgh_2023_11_041 crossref_primary_10_5582_ddt_2024_01088 crossref_primary_10_3357_AMHP_6226_2023 crossref_primary_10_1136_rmdopen_2024_004246 crossref_primary_10_3390_jcm13247677 crossref_primary_10_3389_fimmu_2022_977265 crossref_primary_10_1097_BOR_0000000000000870 crossref_primary_10_3389_fcvm_2022_884636 crossref_primary_10_1080_07853890_2024_2332406 crossref_primary_10_1016_j_coph_2022_102234 crossref_primary_10_1177_09733698241239709 crossref_primary_10_28982_josam_7991 crossref_primary_10_1007_s40744_023_00557_x crossref_primary_10_1097_RHU_0000000000001945 crossref_primary_10_3390_jcm12030957 crossref_primary_10_18553_jmcp_2023_23209 crossref_primary_10_1093_rheumatology_keae213 crossref_primary_10_4081_reumatismo_2022_1511 crossref_primary_10_1002_acr_25106 crossref_primary_10_1093_rheumatology_kead489 crossref_primary_10_1016_j_eujim_2023_102227 crossref_primary_10_1016_j_berh_2021_101725 crossref_primary_10_1002_acr_25340 crossref_primary_10_1016_j_biopha_2023_114388 crossref_primary_10_1136_rmdopen_2023_004007 crossref_primary_10_1007_s00393_025_01628_w crossref_primary_10_1016_j_jbspin_2023_105671 crossref_primary_10_1186_s13075_024_03358_x crossref_primary_10_3390_jcm13051250 crossref_primary_10_30895_2312_7821_2024_416 crossref_primary_10_4103_jehp_jehp_1384_24 crossref_primary_10_3389_fphar_2024_1387585 crossref_primary_10_1177_23971983251324803 crossref_primary_10_1002_acr_25457 crossref_primary_10_1097_RHU_0000000000002013 crossref_primary_10_3390_biomedicines12071608 crossref_primary_10_1016_j_jep_2023_116211 crossref_primary_10_1016_j_reumae_2022_12_002 crossref_primary_10_1093_rheumatology_kead478 crossref_primary_10_3389_fimmu_2024_1391848 crossref_primary_10_1007_s10067_023_06773_8 crossref_primary_10_1097_RHU_0000000000002130 crossref_primary_10_1007_s10067_023_06709_2 crossref_primary_10_1002_msc_1612 crossref_primary_10_1007_s40266_024_01175_0 crossref_primary_10_1186_s41232_022_00221_x crossref_primary_10_1186_s12890_024_03287_0 crossref_primary_10_1007_s00296_023_05312_7 crossref_primary_10_1093_rheumatology_kead232 crossref_primary_10_1080_08998280_2022_2139955 crossref_primary_10_1093_rheumatology_kead106 crossref_primary_10_1016_j_abst_2024_09_002 crossref_primary_10_1080_00015385_2023_2279409 crossref_primary_10_3928_23258160_20240908_01 crossref_primary_10_1111_1756_185X_14695 crossref_primary_10_1038_s41598_024_65199_7 crossref_primary_10_1002_msc_1882 crossref_primary_10_1111_apt_18194 crossref_primary_10_1002_pds_5546 crossref_primary_10_1038_s41591_022_01857_5 crossref_primary_10_47360_1995_4484_2023_165_180 crossref_primary_10_4997_jrcpe_2021_306 crossref_primary_10_1080_14712598_2024_2358165 crossref_primary_10_1093_postmj_qgae176 crossref_primary_10_12677_tcm_2025_141040 crossref_primary_10_1002_acr_25117 crossref_primary_10_1016_j_reuma_2021_08_001 crossref_primary_10_3390_medicina60121982 crossref_primary_10_3390_ph16040587 crossref_primary_10_1136_rmdopen_2023_004037 crossref_primary_10_1007_s10067_024_07285_9 crossref_primary_10_1111_1756_185X_15413 crossref_primary_10_36290_med_2022_001 crossref_primary_10_1093_rheumatology_kead694 crossref_primary_10_1002_acr2_70013 crossref_primary_10_1093_rheumatology_keac477 crossref_primary_10_3899_jrheum_220152 crossref_primary_10_1111_cts_70156 crossref_primary_10_3389_fimmu_2024_1333993 crossref_primary_10_17116_profmed20242711140 crossref_primary_10_1002_med_21990 crossref_primary_10_1007_s10067_024_06932_5 crossref_primary_10_3390_diagnostics14040452 crossref_primary_10_1084_jem_20230559 crossref_primary_10_1016_j_ejphar_2023_175997 crossref_primary_10_1093_rap_rkae132 crossref_primary_10_1097_MD_0000000000039776 crossref_primary_10_1097_MD_0000000000040512 crossref_primary_10_1111_cts_13649 crossref_primary_10_1111_jgh_16725 crossref_primary_10_1007_s40290_021_00396_7 crossref_primary_10_1016_j_ajpc_2022_100380 crossref_primary_10_3390_diagnostics13010148 crossref_primary_10_7759_cureus_65056 crossref_primary_10_2147_JMDH_S459555 crossref_primary_10_1002_art_42764 crossref_primary_10_3389_fimmu_2024_1466276 crossref_primary_10_52880_sagakaderg_1072311 crossref_primary_10_1038_s41584_024_01107_7 crossref_primary_10_1097_MD_0000000000038448 crossref_primary_10_1111_1756_185X_15319 crossref_primary_10_3390_jcm13020601 crossref_primary_10_1007_s11926_025_01184_x crossref_primary_10_1016_j_jval_2024_08_001 crossref_primary_10_1080_08998280_2025_2473863 crossref_primary_10_1177_21501351221141436 crossref_primary_10_3390_nu16162640 crossref_primary_10_1007_s40744_023_00591_9 crossref_primary_10_1055_a_2279_6231 crossref_primary_10_1186_s13550_025_01203_z crossref_primary_10_1093_rheumatology_kead431 crossref_primary_10_1093_rheumatology_kead430 crossref_primary_10_4103_injr_injr_159_22 crossref_primary_10_1016_j_reuma_2024_05_007 crossref_primary_10_1186_s13075_023_03151_2 crossref_primary_10_1002_art_42730 crossref_primary_10_1093_rheumatology_kead307 crossref_primary_10_18553_jmcp_2023_29_7_732 crossref_primary_10_1080_13697137_2023_2276201 crossref_primary_10_1111_1756_185X_15102 crossref_primary_10_1515_dmpt_2021_0190 crossref_primary_10_1080_14737159_2022_2140586 crossref_primary_10_1111_1756_185X_70123 crossref_primary_10_3389_fmed_2024_1418243 crossref_primary_10_1016_j_intimp_2023_110959 crossref_primary_10_1007_s40744_023_00549_x crossref_primary_10_1002_art_42864 crossref_primary_10_18332_pne_161867 crossref_primary_10_1097_MD_0000000000029974 crossref_primary_10_1186_s13075_024_03337_2 crossref_primary_10_34133_bmef_0102 crossref_primary_10_1002_art_42507 crossref_primary_10_1016_j_reumae_2023_05_006 crossref_primary_10_1007_s10067_022_06185_0 crossref_primary_10_3389_fimmu_2024_1352251 crossref_primary_10_3389_fddsv_2024_1338535 crossref_primary_10_3390_jpm13111550 crossref_primary_10_1007_s10067_025_07350_x crossref_primary_10_1177_1759720X221091450 crossref_primary_10_3390_ijms23052583 crossref_primary_10_3390_jcm14020568 crossref_primary_10_1111_bcp_16365 crossref_primary_10_7326_M23_0192 crossref_primary_10_1080_1750743X_2024_2426972 crossref_primary_10_1186_s41927_023_00329_8 crossref_primary_10_1002_acr_25187 crossref_primary_10_1016_S2665_9913_24_00227_3 crossref_primary_10_1002_acr_25181 crossref_primary_10_1515_rir_2024_0028 crossref_primary_10_1016_j_reumae_2024_02_009 crossref_primary_10_1016_j_omtn_2022_12_008 crossref_primary_10_1093_mr_road033 crossref_primary_10_1002_ccr3_9638 crossref_primary_10_4103_ijem_ijem_410_23 crossref_primary_10_1007_s40744_025_00753_x crossref_primary_10_1007_s10067_022_06221_z crossref_primary_10_1136_ard_2022_223429 crossref_primary_10_3389_fmed_2024_1338947 crossref_primary_10_1016_j_jep_2024_118736 crossref_primary_10_3389_fimmu_2024_1447337 crossref_primary_10_1080_13696998_2023_2299176 crossref_primary_10_1093_rheumatology_keac547 crossref_primary_10_1093_rheumatology_kead515 crossref_primary_10_1016_j_berh_2024_101974 crossref_primary_10_1080_17460751_2024_2443352 crossref_primary_10_3390_bs14040327 crossref_primary_10_1097_PRS_0000000000011340 crossref_primary_10_1136_ard_2022_223679 crossref_primary_10_1007_s40744_023_00597_3 crossref_primary_10_1016_j_reuma_2023_09_012 crossref_primary_10_1093_ije_dyac085 crossref_primary_10_1093_mr_road045 crossref_primary_10_4103_jdras_jdras_177_24 crossref_primary_10_1093_mr_roae019 crossref_primary_10_1111_1756_185X_14382 crossref_primary_10_14412_1996_7012_2024_4_106_114 crossref_primary_10_1093_rheumatology_keac533 crossref_primary_10_1002_art_42653 crossref_primary_10_1093_rheumatology_keac657 crossref_primary_10_1002_msc_1804 crossref_primary_10_1002_msc_1928 crossref_primary_10_1007_s40744_024_00658_1 crossref_primary_10_1007_s11926_023_01116_7 crossref_primary_10_1007_s40801_024_00416_3 crossref_primary_10_14309_crj_0000000000001285 crossref_primary_10_1021_acsnano_2c04491 crossref_primary_10_28982_josam_984025 crossref_primary_10_1007_s40744_023_00606_5 crossref_primary_10_1002_acr2_11584 crossref_primary_10_1093_mr_road055 crossref_primary_10_3389_fchem_2023_1181159 crossref_primary_10_1177_15598276221116063 crossref_primary_10_1093_mr_roac089 crossref_primary_10_1007_s10067_023_06623_7 crossref_primary_10_3390_biomedicines11030930 crossref_primary_10_3389_fmed_2024_1285772 crossref_primary_10_1007_s40264_023_01333_0 crossref_primary_10_1093_rheumatology_keac645 crossref_primary_10_1038_s41584_021_00721_z crossref_primary_10_7759_cureus_80634 crossref_primary_10_1002_art_42300 crossref_primary_10_1186_s13075_023_03165_w crossref_primary_10_2147_BTT_S252575 crossref_primary_10_4078_jrd_22_0024 crossref_primary_10_1002_acr2_11335 crossref_primary_10_1007_s40744_023_00618_1 crossref_primary_10_3390_ijms25052682 crossref_primary_10_1007_s40744_023_00596_4 crossref_primary_10_1038_s41598_023_42324_6 crossref_primary_10_1093_mr_roaf007 crossref_primary_10_1093_mr_roaf006 crossref_primary_10_3390_cells10112857 crossref_primary_10_1080_14712598_2024_2377298 crossref_primary_10_1186_s12969_024_01046_3 crossref_primary_10_1002_adfm_202211644 crossref_primary_10_3389_fphar_2023_1279215 crossref_primary_10_1093_rheumatology_keac515 crossref_primary_10_1007_s40259_022_00542_w crossref_primary_10_1097_MD9_0000000000000341 crossref_primary_10_3389_fmed_2022_991677 crossref_primary_10_1016_j_rhum_2023_06_005 crossref_primary_10_2147_JIR_S344393 crossref_primary_10_3390_ijms252413430 crossref_primary_10_1093_mr_roae043 crossref_primary_10_1016_j_semarthrit_2023_152302 crossref_primary_10_1093_mr_roae049 crossref_primary_10_4330_wjc_v15_i5_217 crossref_primary_10_1111_jcpt_13740 crossref_primary_10_3899_jrheum_2024_0383 crossref_primary_10_1007_s40744_024_00736_4 crossref_primary_10_3899_jrheum_220782 crossref_primary_10_7759_cureus_35622 crossref_primary_10_1016_j_phymed_2022_154236 crossref_primary_10_4103_sjcp_sjcp_24_24 crossref_primary_10_1002_art_42245 crossref_primary_10_1016_j_jhsa_2022_08_010 crossref_primary_10_33590_emj_10308161 crossref_primary_10_1016_S2665_9913_23_00298_9 crossref_primary_10_1093_mr_roae051 crossref_primary_10_1186_s12962_024_00592_7 crossref_primary_10_21518_2079_701X_2021_19_155_162 crossref_primary_10_1186_s12913_023_10298_w crossref_primary_10_3389_fmed_2022_1112872 crossref_primary_10_1177_20499361221135155 crossref_primary_10_1136_ard_2022_223356 crossref_primary_10_1136_bmjophth_2024_001898 crossref_primary_10_26641_2307_0404_2023_1_276049 crossref_primary_10_1136_bmj_2022_070856 crossref_primary_10_1002_cdt3_43 crossref_primary_10_54097_ijbls_v3i1_9623 crossref_primary_10_1136_bmjopen_2023_076131 crossref_primary_10_1007_s12668_024_01373_5 crossref_primary_10_1002_art_42336 crossref_primary_10_1186_s13075_022_02851_5 crossref_primary_10_1093_rheumatology_keab763 crossref_primary_10_1111_imj_15816 crossref_primary_10_14283_jpad_2024_78 crossref_primary_10_1097_RHU_0000000000002105 crossref_primary_10_1001_jamanetworkopen_2024_46336 crossref_primary_10_3389_fpain_2022_1018800 crossref_primary_10_18553_jmcp_2024_30_5_480 crossref_primary_10_5114_reum_191791 crossref_primary_10_1186_s43166_022_00153_x crossref_primary_10_3390_healthcare13010071 crossref_primary_10_1002_jcla_24594 crossref_primary_10_1080_14737159_2021_2000394 crossref_primary_10_1093_mr_road098 crossref_primary_10_3899_jrheum_220209 crossref_primary_10_1056_NEJMcpc2312725 crossref_primary_10_1097_IOP_0000000000002573 crossref_primary_10_1016_j_semarthrit_2022_152002 crossref_primary_10_2147_JIR_S476847 crossref_primary_10_2174_2772432817666220202115623 crossref_primary_10_47360_1995_4484_2022_505_518 crossref_primary_10_3389_fphar_2023_1276038 crossref_primary_10_1007_s10067_021_05973_4 crossref_primary_10_1136_bmjopen_2024_088869 crossref_primary_10_1016_j_reumae_2024_09_002 crossref_primary_10_1007_s40266_025_01190_9 crossref_primary_10_7759_cureus_22768 crossref_primary_10_1007_s00393_025_01620_4 crossref_primary_10_1016_j_jep_2023_116350 crossref_primary_10_1080_14737167_2022_2117690 crossref_primary_10_3899_jrheum_210992 crossref_primary_10_1002_acr2_11376 crossref_primary_10_1007_s40264_024_01461_1 crossref_primary_10_1097_NSG_0000000000000063 crossref_primary_10_1111_1756_185X_15176 crossref_primary_10_2174_1573397119666230828160108 crossref_primary_10_1016_j_hcl_2024_07_002 crossref_primary_10_1186_s12916_023_02746_5 |
| Cites_doi | 10.1513/AnnalsATS.201804-245OC 10.1136/ard.2008.092668 10.1016/j.semarthrit.2018.12.006 10.1136/annrheumdis-2014-205228 10.1007/s00296-010-1525-z 10.3899/jrheum.140103 10.1136/annrheumdis-2012-201612 10.1002/acr.24042 10.1161/01.CIR.0000077913.60364.D2 10.1002/acr.22944 10.1002/hep.29800 10.7326/0003-4819-127-5-199709010-00003 10.1136/bmj.329.7477.1266 10.1016/j.jclinepi.2015.09.006 10.1007/s40259-017-0231-8 10.7326/M18-2217 10.1136/annrheumdis-2011-200690 10.1002/art.34498 10.1002/cld.722 10.1016/j.jclinepi.2013.02.003 10.1056/NEJMoa1303006 10.1136/ard.2008.092163 10.1002/art.23721 10.1002/art.41384 10.1592/phco.22.13.1157.33525 10.7326/M16-0713 10.1136/rmdopen-2018-000870 10.1002/art.23716 10.1038/srep29443 10.1002/acr.22758 10.1002/acr.21641 10.1136/thoraxjnl-2014-206470 10.1136/annrheumdis-2015-207628 10.1503/cmaj.090449 10.1002/1529-0131(199807)41:7<1327::AID-ART30>3.0.CO;2-T 10.1002/art.40149 10.1002/art.21984 10.1093/rheumatology/kew344 10.1016/S0140-6736(12)60027-0 10.1002/acr.24130 10.1007/s00296-017-3749-7 10.1136/bmj.h1389 10.1016/j.semarthrit.2013.09.005 10.1161/01.CIR.0000124490.27666.B2 10.1136/annrheumdis-2013-204882 10.1002/art.23913 10.1136/annrheumdis-2011-200702 10.1136/bmj.39489.470347.AD 10.1186/s13075-017-1266-4 10.1136/annrheumdis-2014-205726 10.1136/ard.2008.099861 10.1136/annrheumdis-2018-213731 10.1136/annrheumdis-2015-209057 10.1002/acr.23759 10.1002/art.40196 10.1056/NEJMoa2008250 10.1002/art.39480 10.1007/s00296-009-0931-6 10.1002/art.38210 10.1002/art.39626 10.1002/art.21716 10.1002/acr2.11064 10.1136/annrheumdis-2016-209285 |
| ContentType | Journal Article |
| Copyright | 2021, American College of Rheumatology 2021, American College of Rheumatology. 2021 American College of Rheumatology |
| Copyright_xml | – notice: 2021, American College of Rheumatology – notice: 2021, American College of Rheumatology. – notice: 2021 American College of Rheumatology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP NAPCQ 7X8 5PM |
| DOI | 10.1002/acr.24596 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Nursing & Allied Health Premium MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2151-4658 |
| EndPage | 939 |
| ExternalDocumentID | PMC9273041 34101387 10_1002_acr_24596 ACR24596 |
| Genre | article Systematic Review Journal Article Practice Guideline Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAMS NIH HHS grantid: K23 AR064372 |
| GroupedDBID | .3N .GA .Y3 0R~ 10A 1OC 24P 31~ 33P 4.4 50Z 51W 51X 52N 52O 52P 52R 52S 52T 52W 52X 53G 5VS 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCUV ABIJN ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADMGS ADOZA ADXAS ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BRXPI BY8 D-6 D-7 D-E D-F DCZOG DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S GODZA H.X HF~ HGLYW HZ~ J0M J5H KBYEO LATKE LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N04 N05 NF~ O66 O9- P2P P2W P2X P2Z P4B P4D Q.N QB0 ROL SUPJJ TEORI UB1 V9Y W8V W99 WBKPD WHWMO WIK WOHZO WQJ WVDHM WXI WXSBR XG1 ZZTAW ~WT AAYXX ABJNI AEYWJ AGHNM AGYGG CITATION OVD CGR CUY CVF ECM EIF NPM 7QP AAMMB AEFGJ AGXDD AIDQK AIDYY NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c5096-5e26e3e8c6c3c43d9bee3e25cda95ede9fba434bb776af66a3ea91bb9daac8c53 |
| IEDL.DBID | DR2 |
| ISSN | 2151-464X 2151-4658 |
| IngestDate | Thu Aug 21 18:06:28 EDT 2025 Fri Jul 11 01:46:28 EDT 2025 Fri Jul 25 06:27:34 EDT 2025 Thu Apr 03 07:06:57 EDT 2025 Tue Jul 01 01:38:02 EDT 2025 Thu Apr 24 23:11:20 EDT 2025 Wed Jan 22 16:28:39 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | 2021, American College of Rheumatology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5096-5e26e3e8c6c3c43d9bee3e25cda95ede9fba434bb776af66a3ea91bb9daac8c53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Instructional Material/Guideline-3 content type line 23 ObjectType-Undefined-4 All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. Fraenkel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. AUTHOR CONTRIBUTIONS Acquisition of data. Fraenkel, Bathon, England, St.Clair, Carandang, Deane, Genovese, Kerr, Kremer, J. Singh, Sparks, Al-Gibbawi, Baker, Barton, Cappelli, George, Johnson, Kahale, Karam, Khamis, Navarro-Millán, Mirza, Schwab, N. Singh, Turgunbaev, Turner, Yaacoub, Akl. Study conception and design. Fraenkel, Bathon, England, St.Clair, Deane, Genovese, Kerr, Kremer, Sparks, Venkatachalam, Weinblatt, George, Johnson, Turner, Yaacoub, Akl. Analysis and interpretation of data. Fraenkel, Bathon, England, St.Clair, Arayssi, Deane, Genovese, Huston, Kerr, Kremer, Nakamura, Russell, J. Singh, Smith, Sparks, Venkatachalam, Weinblatt, Al-Gibbawi, Barbour, Barton, Chamseddine, Johnson, Kahale, Karam, Khamis, Navarro-Millán, Mirza, Schwab, N. Singh, Turgunbaev, Yaacoub, Akl. |
| ORCID | 0000-0003-0799-7563 0000-0002-9540-6614 0000-0002-9649-3588 0000-0002-5556-4618 0000-0002-5567-7065 0000-0001-7695-2022 0000-0002-0159-6374 0000-0001-6674-9901 0000-0003-3485-0006 0000-0003-0591-2976 0000-0002-6612-0473 0000-0002-6148-610X 0000-0003-2795-7059 0000-0003-0819-1561 0000-0003-0546-6742 0000-0002-0398-2308 0000-0003-2211-4861 0000-0001-5294-4503 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9273041 |
| PMID | 34101387 |
| PQID | 2545587345 |
| PQPubID | 2045195 |
| PageCount | 16 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9273041 proquest_miscellaneous_2539211983 proquest_journals_2545587345 pubmed_primary_34101387 crossref_citationtrail_10_1002_acr_24596 crossref_primary_10_1002_acr_24596 wiley_primary_10_1002_acr_24596_ACR24596 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2021 |
| PublicationDateYYYYMMDD | 2021-07-01 |
| PublicationDate_xml | – month: 07 year: 2021 text: July 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Arthritis care & research (2010) |
| PublicationTitleAlternate | Arthritis Care Res (Hoboken) |
| PublicationYear | 2021 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2009; 68 2019; 71 2019; 170 2014; 91 2019; 5 2013; 66 2020; 383 2017; 69 2015; 70 2006; 55 2019; 1 2013; 369 2019; 78 2008; 59 2016; 75 2016; 70 2010; 182 1998; 41 2004; 329 2004; 109 2018; 67 2012; 32 2014; 66 2014; 43 2016; 55 2015; 350 2012; 71 2017; 31 2016; 6 1997; 127 2009; 30 2003; 107 2017; 37 2020; 72 2017; 76 2013; 72 2002; 22 2019; 49 2008; 336 2017; 19 2014; 73 2017; 167 2012; 379 2018; 11 2016; 68 2012; 64 2018; 15 e_1_2_9_31_1 e_1_2_9_52_1 e_1_2_9_50_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_56_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_54_1 e_1_2_9_39_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_58_1 e_1_2_9_18_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_20_1 e_1_2_9_62_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_66_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_4_1 e_1_2_9_60_1 e_1_2_9_2_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_30_1 e_1_2_9_53_1 e_1_2_9_51_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_57_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_55_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_59_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_63_1 e_1_2_9_40_1 e_1_2_9_61_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_67_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_65_1 e_1_2_9_7_1 e_1_2_9_5_1 e_1_2_9_3_1 e_1_2_9_9_1 e_1_2_9_25_1 Curtis JR (e_1_2_9_14_1) e_1_2_9_27_1 e_1_2_9_48_1 e_1_2_9_29_1 36125998 - Am Fam Physician. 2022 Sep;106(3):340-342 |
| References_xml | – volume: 68 start-page: 1094 year: 2009 end-page: 9 article-title: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature publication-title: Ann Rheum Dis – volume: 43 start-page: 613 year: 2014 end-page: 26 article-title: Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review publication-title: Semin Arthritis Rheum – volume: 109 start-page: 1594 year: 2004 end-page: 602 article-title: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) publication-title: Circulation – volume: 78 start-page: 25 year: 2019 end-page: 30 article-title: How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies publication-title: Ann Rheum Dis – volume: 1 start-page: 424 year: 2019 end-page: 32 article-title: Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease‐modifying antirheumatic drugs publication-title: ACR Open Rheumatol – volume: 182 start-page: E839 year: 2010 end-page: 42 article-title: AGREE II: advancing guideline development, reporting and evaluation in health care publication-title: CMAJ – volume: 76 start-page: 96 year: 2017 end-page: 104 article-title: Certolizumab pegol in combination with dose‐optimised methotrexate in DMARD‐naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1‐year results from C‐EARLY, a randomised, double‐blind, placebo‐controlled phase III study publication-title: Ann Rheum Dis – volume: 37 start-page: 1469 year: 2017 end-page: 79 article-title: Maintenance of remission with combination etanercept‐DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‐to‐target study conducted in regions with limited biologic access publication-title: Rheumatol Int – volume: 68 start-page: 26 year: 2016 end-page: 35 article-title: When patients write the guidelines: patient panel recommendations for the treatment of rheumatoid arthritis publication-title: Arthritis Care Res (Hoboken) – volume: 71 start-page: 1326 year: 2019 end-page: 35 article-title: Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine publication-title: Arthritis Care Res (Hoboken) – volume: 91 start-page: 56 year: 2014 end-page: 64 article-title: Tuberculosis risk in patients treated with non‐anti‐tumor necrosis factor‐α (TNF‐α) targeted biologics and recently licensed TNF‐α inhibitors: data from clinical trials and national registries publication-title: J Rheumatol Suppl – volume: 32 start-page: 4023 year: 2012 end-page: 6 article-title: A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab publication-title: Rheumatol Int – volume: 72 start-page: 37 year: 2013 end-page: 42 article-title: Mycobacterial diseases and antitumour necrosis factor therapy in USA publication-title: Ann Rheum Dis – volume: 336 start-page: 924 year: 2008 end-page: 6 article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations publication-title: BMJ – volume: 167 start-page: 8 year: 2017 end-page: 16 article-title: Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost‐effectiveness analysis publication-title: Ann Intern Med – volume: 383 start-page: 1511 year: 2020 end-page: 21 article-title: Trial of upadacitinib or abatacept in rheumatoid arthritis publication-title: N Engl J Med – volume: 6 start-page: 29443 year: 2016 article-title: Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: a case‐control study in a TB endemic area publication-title: Sci Rep – volume: 72 start-page: 1607 year: 2020 end-page: 20 article-title: Efficacy and safety of upadacitinib monotherapy in methotrexate‐naive patients with moderately‐to‐severely active rheumatoid arthritis (SELECT‐EARLY): a multicenter, multi‐country, randomized, double‐blind, active comparator–controlled trial publication-title: Arthritis Rheumatol – volume: 41 start-page: 1327 year: 1998 end-page: 8 article-title: Experience with methotrexate‐associated pneumonitis in northeastern England: comment on the article by Kremer et al [letter] publication-title: Arthritis Rheum – volume: 75 start-page: 1081 year: 2016 end-page: 91 article-title: Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial publication-title: Ann Rheum Dis – volume: 68 start-page: 1810 year: 2016 end-page: 7 article-title: Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open‐label randomized controlled trial publication-title: Arthritis Rheumatol – volume: 59 start-page: 762 year: 2008 end-page: 84 article-title: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis publication-title: Arthritis Rheum – volume: 68 start-page: 1105 year: 2009 end-page: 12 article-title: Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non‐biological disease‐modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta‐analysis publication-title: Ann Rheum Dis – volume: 55 start-page: 157 year: 2006 end-page: 9 article-title: Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab publication-title: Arthritis Rheum – volume: 70 start-page: 111 year: 2016 end-page: 22 article-title: A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance publication-title: J Clin Epidemiol – volume: 72 start-page: 461 year: 2020 end-page: 88 article-title: 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases publication-title: Arthritis Care Res (Hoboken) – volume: 67 start-page: 1560 year: 2018 end-page: 99 article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance publication-title: Hepatology – volume: 73 start-page: 1027 year: 2014 end-page: 36 article-title: A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial publication-title: Ann Rheum Dis – volume: 107 start-page: 3133 year: 2003 end-page: 40 article-title: Randomized, double‐blind, placebo‐controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor‐alpha, in patients with moderate‐to‐severe heart failure: results of the anti‐TNF Therapy Against Congestive Heart Failure (ATTACH) trial publication-title: Circulation – volume: 30 start-page: 275 year: 2009 end-page: 6 article-title: Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment publication-title: Rheumatol Int – volume: 69 start-page: 1538 year: 2017 end-page: 51 article-title: 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty publication-title: Arthritis Rheumatol – volume: 73 start-page: 1549 year: 2014 end-page: 51 article-title: Head‐to‐head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug‐exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration publication-title: Ann Rheum Dis – volume: 71 start-page: 1540 year: 2019 end-page: 55 article-title: 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures publication-title: Arthritis Care Res (Hoboken) – volume: 49 start-page: 20 year: 2019 end-page: 6 article-title: The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life publication-title: Semin Arthritis Rheum – volume: 66 start-page: 726 year: 2013 end-page: 35 article-title: GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength publication-title: J Clin Epidemiol – volume: 69 start-page: 313 year: 2017 end-page: 22 article-title: Persistence with conventional triple therapy versus a tumor necrosis factor inhibitor and methotrexate in US veterans with rheumatoid arthritis publication-title: Arthritis Care Res (Hoboken) – volume: 379 start-page: 1712 year: 2012 end-page: 20 article-title: Conventional combination treatment versus biological treatment in methotrexate‐refractory early rheumatoid arthritis: 2 year follow‐up of the randomised, non‐blinded, parallel‐group Swefot trial publication-title: Lancet – volume: 369 start-page: 307 year: 2013 end-page: 18 article-title: Therapies for active rheumatoid arthritis after methotrexate failure publication-title: N Engl J Med – volume: 127 start-page: 356 year: 1997 end-page: 64 article-title: Risk factors for methotrexate‐induced lung injury in patients with rheumatoid arthritis: a multicenter, case‐control study publication-title: Ann Intern Med – volume: 59 start-page: 794 year: 2008 end-page: 9 article-title: Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate publication-title: Arthritis Rheum – volume: 59 start-page: 1074 year: 2008 end-page: 81 article-title: Use of nonbiologic disease‐modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis publication-title: Arthritis Rheum – volume: 71 start-page: 1128 year: 2012 end-page: 33 article-title: Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis publication-title: Ann Rheum Dis – volume: 76 start-page: 386 year: 2017 end-page: 91 article-title: Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers publication-title: Ann Rheum Dis – volume: 55 start-page: ii3 issue: Suppl 2 year: 2016 end-page: 5 article-title: Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies publication-title: Rheumatology (Oxford) – article-title: Real‐world outcomes associated with triple therapy versus tumor necrosis factor inhibitor/methotrexate therapy publication-title: Arthritis Care Res (Hoboken) – volume: 68 start-page: 1119 year: 2009 end-page: 24 article-title: Dose‐related patterns of glucocorticoid‐induced side effects publication-title: Ann Rheum Dis – volume: 15 start-page: 1169 year: 2018 end-page: 76 article-title: Association between inhaled corticosteroid use and pulmonary nontuberculous mycobacterial infection publication-title: Ann Am Thorac Soc – volume: 75 start-page: 52 year: 2016 end-page: 8 article-title: Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 69 start-page: 1937 year: 2017 end-page: 48 article-title: A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis publication-title: Arthritis Rheumatol – volume: 72 start-page: 844 year: 2013 end-page: 50 article-title: Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD‐naive patients with early rheumatoid arthritis: HIT HARD, an investigator‐initiated study publication-title: Ann Rheum Dis – volume: 350 start-page: h1389 year: 2015 article-title: Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial publication-title: BMJ – volume: 11 start-page: 81 year: 2018 article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases publication-title: Clin Liver Dis (Hoboken) – volume: 329 start-page: 1266 year: 2004 article-title: Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab publication-title: BMJ – volume: 170 start-page: 825 year: 2019 end-page: 36 article-title: Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty: a cohort study publication-title: Ann Intern Med – volume: 31 start-page: 299 year: 2017 end-page: 316 article-title: Immunogenicity of biologics in chronic inflammatory diseases: a systematic review publication-title: BioDrugs – volume: 22 start-page: 1157 year: 2002 end-page: 62 article-title: A review of methotrexate‐induced accelerated nodulosis publication-title: Pharmacotherapy – volume: 70 start-page: 677 year: 2015 end-page: 82 article-title: Increased risk of mycobacterial infections associated with anti‐rheumatic medications publication-title: Thorax – volume: 64 start-page: 625 year: 2012 end-page: 39 article-title: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis publication-title: Arthritis Care Res (Hoboken) – volume: 5 year: 2019 article-title: Window of opportunity in rheumatoid arthritis—definitions and supporting evidence: from old to new perspectives publication-title: RMD Open – volume: 66 start-page: 264 year: 2014 end-page: 72 article-title: Glucocorticoid dose thresholds associated with all‐cause and cardiovascular mortality in rheumatoid arthritis publication-title: Arthritis Rheumatol – volume: 55 start-page: 420 year: 2006 end-page: 6 article-title: Population‐based assessment of adverse events associated with long‐term glucocorticoid use publication-title: Arthritis Rheum – volume: 68 start-page: 1 year: 2016 end-page: 26 article-title: 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis publication-title: Arthritis Rheumatol – volume: 64 start-page: 2824 year: 2012 end-page: 35 article-title: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis Trial publication-title: Arthritis Rheum – volume: 19 start-page: 68 year: 2017 article-title: Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies publication-title: Arthritis Res Ther – ident: e_1_2_9_55_1 doi: 10.1513/AnnalsATS.201804-245OC – ident: e_1_2_9_25_1 doi: 10.1136/ard.2008.092668 – ident: e_1_2_9_26_1 doi: 10.1016/j.semarthrit.2018.12.006 – ident: e_1_2_9_24_1 doi: 10.1136/annrheumdis-2014-205228 – ident: e_1_2_9_42_1 doi: 10.1007/s00296-010-1525-z – ident: e_1_2_9_58_1 doi: 10.3899/jrheum.140103 – ident: e_1_2_9_22_1 doi: 10.1136/annrheumdis-2012-201612 – ident: e_1_2_9_11_1 doi: 10.1002/acr.24042 – ident: e_1_2_9_47_1 doi: 10.1161/01.CIR.0000077913.60364.D2 – ident: e_1_2_9_31_1 doi: 10.1002/acr.22944 – ident: e_1_2_9_49_1 doi: 10.1002/hep.29800 – ident: e_1_2_9_40_1 doi: 10.7326/0003-4819-127-5-199709010-00003 – ident: e_1_2_9_43_1 doi: 10.1136/bmj.329.7477.1266 – ident: e_1_2_9_8_1 doi: 10.1016/j.jclinepi.2015.09.006 – ident: e_1_2_9_38_1 doi: 10.1007/s40259-017-0231-8 – ident: e_1_2_9_54_1 doi: 10.7326/M18-2217 – ident: e_1_2_9_14_1 article-title: Real‐world outcomes associated with triple therapy versus tumor necrosis factor inhibitor/methotrexate therapy publication-title: Arthritis Care Res (Hoboken) – ident: e_1_2_9_59_1 doi: 10.1136/annrheumdis-2011-200690 – ident: e_1_2_9_28_1 doi: 10.1002/art.34498 – ident: e_1_2_9_50_1 doi: 10.1002/cld.722 – ident: e_1_2_9_7_1 doi: 10.1016/j.jclinepi.2013.02.003 – ident: e_1_2_9_29_1 doi: 10.1056/NEJMoa1303006 – ident: e_1_2_9_66_1 doi: 10.1136/ard.2008.092163 – ident: e_1_2_9_3_1 doi: 10.1002/art.23721 – ident: e_1_2_9_17_1 doi: 10.1002/art.41384 – ident: e_1_2_9_39_1 doi: 10.1592/phco.22.13.1157.33525 – ident: e_1_2_9_27_1 doi: 10.7326/M16-0713 – ident: e_1_2_9_13_1 doi: 10.1136/rmdopen-2018-000870 – ident: e_1_2_9_61_1 doi: 10.1002/art.23716 – ident: e_1_2_9_56_1 doi: 10.1038/srep29443 – ident: e_1_2_9_67_1 doi: 10.1002/acr.22758 – ident: e_1_2_9_4_1 doi: 10.1002/acr.21641 – ident: e_1_2_9_57_1 doi: 10.1136/thoraxjnl-2014-206470 – ident: e_1_2_9_16_1 doi: 10.1136/annrheumdis-2015-207628 – ident: e_1_2_9_10_1 doi: 10.1503/cmaj.090449 – ident: e_1_2_9_41_1 doi: 10.1002/1529-0131(199807)41:7<1327::AID-ART30>3.0.CO;2-T – ident: e_1_2_9_5_1 doi: 10.1002/art.40149 – ident: e_1_2_9_65_1 doi: 10.1002/art.21984 – ident: e_1_2_9_64_1 doi: 10.1093/rheumatology/kew344 – ident: e_1_2_9_30_1 doi: 10.1016/S0140-6736(12)60027-0 – ident: e_1_2_9_6_1 doi: 10.1002/acr.24130 – ident: e_1_2_9_33_1 doi: 10.1007/s00296-017-3749-7 – ident: e_1_2_9_35_1 doi: 10.1136/bmj.h1389 – ident: e_1_2_9_46_1 doi: 10.1016/j.semarthrit.2013.09.005 – ident: e_1_2_9_48_1 doi: 10.1161/01.CIR.0000124490.27666.B2 – ident: e_1_2_9_23_1 doi: 10.1136/annrheumdis-2013-204882 – ident: e_1_2_9_52_1 doi: 10.1002/art.23913 – ident: e_1_2_9_53_1 doi: 10.1136/annrheumdis-2011-200702 – ident: e_1_2_9_19_1 – ident: e_1_2_9_9_1 doi: 10.1136/bmj.39489.470347.AD – ident: e_1_2_9_12_1 doi: 10.1186/s13075-017-1266-4 – ident: e_1_2_9_36_1 doi: 10.1136/annrheumdis-2014-205726 – ident: e_1_2_9_20_1 doi: 10.1136/ard.2008.099861 – ident: e_1_2_9_32_1 doi: 10.1136/annrheumdis-2018-213731 – ident: e_1_2_9_21_1 doi: 10.1136/annrheumdis-2015-209057 – ident: e_1_2_9_15_1 doi: 10.1002/acr.23759 – ident: e_1_2_9_37_1 doi: 10.1002/art.40196 – ident: e_1_2_9_60_1 doi: 10.1056/NEJMoa2008250 – ident: e_1_2_9_2_1 doi: 10.1002/art.39480 – ident: e_1_2_9_45_1 doi: 10.1007/s00296-009-0931-6 – ident: e_1_2_9_18_1 – ident: e_1_2_9_63_1 doi: 10.1002/art.38210 – ident: e_1_2_9_34_1 doi: 10.1002/art.39626 – ident: e_1_2_9_44_1 doi: 10.1002/art.21716 – ident: e_1_2_9_51_1 doi: 10.1002/acr2.11064 – ident: e_1_2_9_62_1 doi: 10.1136/annrheumdis-2016-209285 – reference: 36125998 - Am Fam Physician. 2022 Sep;106(3):340-342 |
| SSID | ssj0000328839 |
| Score | 2.7207243 |
| SecondaryResourceType | review_article |
| Snippet | Objective
To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.
Methods
We developed clinically relevant population,... To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator,... ObjectiveTo develop updated guidelines for the pharmacologic management of rheumatoid arthritis.MethodsWe developed clinically relevant population,... To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.OBJECTIVETo develop updated guidelines for the pharmacologic management... Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide general guidance for commonly... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 924 |
| SubjectTerms | Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Clinical Decision-Making Congestive heart failure Consensus Coronary artery disease Decision making Decision Support Techniques Glucocorticoids Humans Immunoproliferative diseases Literature reviews Liver diseases Lung diseases Lymphocytes Patients Remission Induction Rheumatoid arthritis Rheumatology - trends Treatment Outcome |
| Title | 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Facr.24596 https://www.ncbi.nlm.nih.gov/pubmed/34101387 https://www.proquest.com/docview/2545587345 https://www.proquest.com/docview/2539211983 https://pubmed.ncbi.nlm.nih.gov/PMC9273041 |
| Volume | 73 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CDqWXPtKX2ySopYdevFnrZYmeQh4NhfSwJLCFgtHLbEjxlmR96a-vRn4k2zQQerPRCFnSjPVpZvQJ4KMpdKhlaXPNAnqrbJ0b5Vxel4bzWklvPZ5GPv0mT87517mYb8Dn4SxMxw8xOtzQMtL_Gg3c2Ou9G9JQ464mlAuNdNsFk8ibfzijo38FeeJUukgMF7WcSz4fiIWmdG-svL4c3cGYd1Mlb0PYtAYdP4Ufw9d3qSeXk3ZlJ-73X8SO_9m9Z_Ckx6Zkv1Om57ARmi14dNpH31_AdxqXajLEeEjvcyDLmswWoY3QN7noyZcWqbNiDRIBMYkAk5wN2ey3ZS88trRIpEov4fz46OzgJO-vZsgd8sXkIlAZ4uw66ZjjzGsb4isVzhstgg-6toYzbm1ZSlNLaVgwurBWe2OccoK9gs1m2YQ3QIqI8ZCkzIcp40GpuKUK3ElPy5oLqlwGn4YZqlzPW47XZ_ysOsZlWsWhqtJQZfBhFP3VkXX8S2h7mOaqt9frKm6ThVAl4yKD92NxtDQMn5gmLFuUiViyKLRiGbzutGJsJWIBDPmWGZRr-jIKIIv3eklzsUhs3joCyCkvYjeTOtz_4dX-wSw9vH246Dt4jKrR5Rdvw-bqqg07EUWt7G4ylz-05hpD |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3oVAAYM4cMl241dsiUtVKAt0e1htpeWAIttxtFWrLCqbC78ej_OgS0FC3BJ5LMf2TPx5ZvwZ4LXJtK9kblPNPHqrbJUa5Vxa5YbzSsnSlngaeXosJyf800IstuBtfxam5YcYHG5oGfF_jQaODum9X6yhxl2MKBdaXoPrPAAN3Hq9m9HBw4JMcSpeJYbLWsolX_TUQmO6N9TeXJCuoMyryZKXQWxchQ7vwNf--9vkk7NRs7Yj9-M3asf_7eBduN3BU7Lf6tM92PL1fbgx7QLwD-ALDas16cM8pHM7kFVFZkvfBPQbvfTkQ4PsWaEGCZiYBIxJ5n1C-2XZ0xJbWkZepYdwcvh-fjBJu9sZUoeUManwVPowwU465jgrtfXhlQpXGi186XVlDWfc2jyXppLSMG90Zq0ujXHKCbYD2_Wq9o-BZAHmIU9Z6ceMe6XCrspzJ0uaV1xQ5RJ4009R4TrqcrxB47xoSZdpEYaqiEOVwKtB9FvL1_Enod1-novOZL8XYacshMoZFwm8HIqDsWEExdR-1aBMgJNZphVL4FGrFkMrAQ5g1DdPIN9QmEEAibw3S-rTZST01gFDjnkWuhn14e8fXuwfzOLDk38XfQE3J_PpUXH08fjzU7iFatKmG-_C9vqi8c8CqFrb59F2fgJIPB5i |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD7UCsUX692prUbxwZfZ7uQ2CT6V1rVeWmRpYQVhyJUtltnS7rz4600yF7tWQXybISdkkpwz-XLOyReA16qQzvNS55K46K3SPlfCmNyXilIvuNU2nkY-OuaHp_TjjM3W4G1_FqblhxgcbtEy0v86GviF9bu_SEOVuRxhyiS_BbcpD0giIqIpHhwskShOpJvE4qqWU05nPbPQGO8OtVfXoxsg82au5HUMmxahySZ86z-_zT35PmqWemR-_Mbs-J_9uwd3O3CK9lptug9rrn4AG0dd-P0hfMVhrUZ9kAd1Tge08Gg6d03AvslHj943kTsr1EABEaOAMNFJn85-XfbMxpbmiVXpEZxO3p3sH-bd3Qy5iYQxOXOYuzC9hhtiKLFSu_CKmbFKMmed9FpRQrUuS64854o4JQutpVXKCMPIY1ivF7V7CqgIIC-ylFk3JtQJEfZUjhpucekpw8Jk8Kafocp0xOXx_ozzqqVcxlUYqioNVQavBtGLlq3jT0Lb_TRXncFeVWGfzJgoCWUZvByKg6nF-Imq3aKJMgFMFoUUJIMnrVYMrQQwEGO-ZQblir4MApHGe7WkPpsnOm8ZEOSYFqGbSR3-_uHV3v40PWz9u-gL2PhyMKk-fzj-9AzuRC1pc423YX152bidgKiW-nmynJ_fNR0R |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=2021+American+College+of+Rheumatology+Guideline+for+the+Treatment+of+Rheumatoid+Arthritis&rft.jtitle=Arthritis+care+%26+research+%282010%29&rft.au=Fraenkel%2C+Liana&rft.au=Bathon%2C+Joan+M&rft.au=England%2C+Bryant+R&rft.au=St+Clair%2C+E+William&rft.date=2021-07-01&rft.eissn=2151-4658&rft.volume=73&rft.issue=7&rft.spage=924&rft_id=info:doi/10.1002%2Facr.24596&rft_id=info%3Apmid%2F34101387&rft.externalDocID=34101387 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2151-464X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2151-464X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2151-464X&client=summon |